Should you buy Revvity (RVTY)?
Updated
Revvity has delivered four consecutive quarterly earnings beats and exceptional free cash flow conversion at 212% of net income with a perfect 9 out of 9 Piotroski score, but with only negative 1.7% upside remaining to the analyst target and 12% short interest, the stock appears fairly priced with downside risk exceeding near-term upside.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
The company beat earnings estimates in all 4 of the last 4 quarters with an average positive surprise of approximately 4.8%, demonstrating consistent ability to deliver at or above the guidance range set for diagnostics and research instrumentation. Earnings | Earnings per share continues to exceed analyst estimates in at least 3 of the next 4 quarters, maintaining the beat track record. | →Stable |
| CounterAverage surprises of only 4.8% in a diagnostics business may reflect analyst conservatism that reverses if revenue growth remains low; the weak growth rate of revenue and earnings creates limited room for sustained outperformance. | ||
Free cash flow conversion runs at 212% of net income and the Piotroski F-Score is a perfect 9 out of 9, indicating exceptional financial health and a business that generates far more cash than reported book earnings across all profitability, leverage, and efficiency dimensions. Quality breakdown | Free cash flow as a percentage of net income remains above 150% and Piotroski score stays at 8 or above over the next 12 months. | →Stable |
| CounterHigh free cash flow relative to net income in a low-growth diagnostics business may reflect capital underinvestment that eventually weighs on competitive positioning; sustained 212% conversion may not be reproducible indefinitely without reinvestment. | ||
Revenue and earnings growth are weak, with the stock trading at or above the analyst consensus take-profit target of $104 from the current $100.55, leaving negative 1.7% upside to consensus and a risk/reward ratio of only 0.5. Bear case | Analyst consensus price target rises above $115 within 12 months as earnings consistency and cash flow quality attract target price increases from analysts covering the diagnostics sector. | →Stable |
| CounterWith a forward price-to-earnings of 17.3 times in a low-growth business and only small positive earnings surprises, analysts have limited justification to raise targets unless revenue growth meaningfully accelerates from current low single-digit rates. | ||
The company beat earnings estimates in all 4 of the last 4 quarters with an average positive surprise of approximately 4.8%, demonstrating consistent ability to deliver at or above the guidance range set for diagnostics and research instrumentation.
→Stable- Expectation
- Earnings per share continues to exceed analyst estimates in at least 3 of the next 4 quarters, maintaining the beat track record.
CounterAverage surprises of only 4.8% in a diagnostics business may reflect analyst conservatism that reverses if revenue growth remains low; the weak growth rate of revenue and earnings creates limited room for sustained outperformance.
Free cash flow conversion runs at 212% of net income and the Piotroski F-Score is a perfect 9 out of 9, indicating exceptional financial health and a business that generates far more cash than reported book earnings across all profitability, leverage, and efficiency dimensions.
→Stable- Expectation
- Free cash flow as a percentage of net income remains above 150% and Piotroski score stays at 8 or above over the next 12 months.
CounterHigh free cash flow relative to net income in a low-growth diagnostics business may reflect capital underinvestment that eventually weighs on competitive positioning; sustained 212% conversion may not be reproducible indefinitely without reinvestment.
Revenue and earnings growth are weak, with the stock trading at or above the analyst consensus take-profit target of $104 from the current $100.55, leaving negative 1.7% upside to consensus and a risk/reward ratio of only 0.5.
→Stable- Expectation
- Analyst consensus price target rises above $115 within 12 months as earnings consistency and cash flow quality attract target price increases from analysts covering the diagnostics sector.
CounterWith a forward price-to-earnings of 17.3 times in a low-growth business and only small positive earnings surprises, analysts have limited justification to raise targets unless revenue growth meaningfully accelerates from current low single-digit rates.
▸ Show 1 more pillar▾ Show fewer
Short interest of 12% combined with rising on-balance volume and a momentum score of 5.1 creates a mixed signal, where accumulation is visible but a meaningful short position suggests some investors are positioned for a decline from current levels.
→Stable- Expectation
- Short interest falls below 8% within 12 months as the earnings consistency reduces the short thesis and forces covering.
CounterShort interest in a low-growth healthcare company near its analyst target often reflects thesis-driven positioning where investors have calculated the expected returns are negative at current prices, making the short position rational rather than contrarian.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company beat earnings estimates in all 4 of the last 4 quarters with an average positive surprise of approximately 4.8%, demonstrating consistent ability to deliver at or above the guidance range set for diagnostics and research instrumentation.
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, breaking the 4-quarter consecutive beat streak.
- P2Free cash flow conversion runs at 212% of net income and the Piotroski F-Score is a perfect 9 out of 9, indicating exceptional financial health and a business that generates far more cash than reported book earnings across all profitability, leverage, and efficiency dimensions.
Trip ifFree cash flow as a percentage of net income falls below 100%, more than 112 percentage points below the current 212% level.
- P3Revenue and earnings growth are weak, with the stock trading at or above the analyst consensus take-profit target of $104 from the current $100.55, leaving negative 1.7% upside to consensus and a risk/reward ratio of only 0.5.
Trip ifAnalyst consensus price target falls below $90, more than 10% below the current stock price of $100.55, indicating downward revision pressure.
- P4Short interest of 12% combined with rising on-balance volume and a momentum score of 5.1 creates a mixed signal, where accumulation is visible but a meaningful short position suggests some investors are positioned for a decline from current levels.
Trip ifShort interest rises above 16% of float, more than 4 percentage points above the current 12%, indicating increased bearish conviction.
How the engine reached this verdict
TrendMatrix's engine output for Revvity, Inc. (RVTY) is SELL_IF_HOLDING with medium conviction, score 5.1/10 at $111.63. The F-path SELL output reflects an overall score of 5.1 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -0.87 is supplementary context, not the trigger.
The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.9>=5.5.
On the bull side: Strong earnings beat streak (4/4). On the bear side: Analyst target reached - limited upside remaining; Weak growth. Active engine warnings: V8: Target reached (-11.5% upside), V9 Gate Failed: ASYMMETRY:-0.9=NEGATIVE.
The engine's exit framework anchors to a tactical sell band near $111.63, with structural invalidation at $103.93. The asymmetric R:R against a reversal hypothesis is 0.01 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates RVTY — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
Bear case
- ▸Analyst target reached - limited upside remaining
- ▸Weak growth